Special Issue

RAS Proteins and Their Regulators in Human Cancer

Message from the Guest Editor

RAS proteins (KRAS, NRAS, and HRAS) are small GTPases that function as binary molecular switches dependent on the loading of GTP (active state) or GDP (inactive state) and which govern critical cellular processes such as cell proliferation, differentiation, and survival. State transitions of RAS proteins are regulated either by intrinsic or GTPase-activating protein (GAP)-stimulated GTP hydrolysis or by guanine nucleotide exchange factor (GEF)-facilitated nucleotide exchange. RAS mutations are found in a large proportion of deadly human tumors, occurring in ~20–30% of malignant tumors overall. Furthermore, RAS mutations are often essential for tumor initiation and maintenance, making RAS a high-priority target in cancer therapy. This Special Issue will cover subjects related to recent progress in RAS proteins, RAS regulators, and their directed therapeutic approaches in cancer therapy. It aims to increase our understanding of RAS regulation and challenges in therapy targeting RAS in human cancers.

Guest Editor

Dr. Zhiwei Zhou

Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA

Deadline for manuscript submissions

10 March 2026

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/234113

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)